Evaxion Earnings Call Transcripts
Fiscal Year 2025
-
Strong 2025 progress included a key MSD in-licensing, Gates Foundation collaboration, and robust clinical and preclinical data across oncology and infectious diseases. Financial stability improved with a $23M year-end cash position and a runway into H2 2027.
-
A clinically validated AI platform enables rapid vaccine discovery, leading to a landmark Merck deal and strong clinical results in melanoma. Cash runway now extends to 2027, with a robust pipeline in cancer and infectious diseases and new leadership driving growth.
-
Q3 saw a transformative MSD deal, strong clinical data for EVX-01, and the addition of EVX-04 to the pipeline. Financials were bolstered by $31.8M in activities, extending cash runway to H2 2027, with ongoing partnership interest across programs.
-
A phase II study of a personalized AI-designed cancer vaccine in advanced melanoma showed a 75% objective response rate and sustained T-cell responses, with most patients maintaining benefit at two years and a favorable safety profile. Booster dosing was key to deepening and sustaining responses.
-
MSD has licensed the AI-discovered EVX-B3 vaccine, providing $7.5 million upfront and extending the cash runway into 2027, with potential milestones up to $592 million. The AI-Immunology platform's scalability and cost-effectiveness are validated, and the pipeline continues to advance in both oncology and infectious diseases.
-
Achieved key milestones with a strong cash position of $14.7 million and reduced operating loss year-over-year. R&D pipeline advanced in both oncology and infectious diseases, with major data readouts and partnership options expected in the second half of 2025.
-
Q1 2025 saw improved cash and equity positions, strong R&D progress, and continued execution on strategic milestones. The business remains on track for key partnerships and pipeline advancements, with a solid cash runway into mid-2026 despite rising macroeconomic risks.
-
Strong cash position and a deepening partnership with Merck support a robust AI-driven pipeline targeting cancer and infectious diseases. Lead asset EVX-01 shows superior clinical results, with key data and partnership milestones expected in H2 2024.
-
The AI Immunology platform enables rapid, high-precision discovery of novel antigens, leading to strong clinical results and strategic partnerships, including a major deal with Merck. Lead asset EVX-01 shows promising efficacy in melanoma, with pivotal trial planning underway.
-
The discussion highlighted the company's AI-driven vaccine platform, strong clinical progress in cancer and infectious disease vaccines, and robust business development strategy. Financial stability and upcoming milestones position the company for significant growth and new partnerships.
Fiscal Year 2024
-
2024 saw major progress in business development, R&D, and financing, highlighted by a key MSD partnership, strong EVX-01 Phase 2 data, and a cash runway to mid-2026. The company targets significant milestones in 2025, including new deals and clinical readouts.
-
Q3 saw major milestones, including a transformative MSD licensing deal and strong clinical progress in both oncology and infectious disease pipelines. Revenue improved, losses narrowed, and cash runway extends into March 2025, though some business development income is delayed to 2025.
-
A transformative partnership with MSD brings significant upfront and milestone payments, validates the AI immunology platform, and accelerates vaccine development for high unmet needs. Recent milestones include positive clinical data and enhanced vaccine design capabilities, supporting a strong financial and strategic outlook.
-
AI-driven vaccine discovery enables rapid, accurate target identification for cancer and infectious diseases, with recent clinical data showing strong efficacy for lead candidates. Strategic partnerships and a pivot toward cash neutrality in 2024 mark a major milestone.
-
Advanced partnership discussions and strong progress in AI-Immunology and vaccine pipeline, with key milestones for EVX-01, EVX-B2, and ERV-based vaccines expected in H2 2024. Cash runway extends into early 2025, with a $14M business development income target for 2024.